{"id":{"repo_id":"wurz-thes","oai_identifier":"oai:opus.bibliothek.uni-wuerzburg.de:823"},"canonical_url":"https://search.dev.ndltd.org/etd/wurz-thes/oai:opus.bibliothek.uni-wuerzburg.de:823","repository":{"repo_id":"wurz-thes","name":"Universität Wüzburg","base_url":"https://opus.bibliothek.uni-wuerzburg.de/oai"},"display":{"title":"Viruslastorientierte Interferon-a-2a-Therapie der chronischen Hepatitis-C-Infektion in Kombination mit Ribavirin und Amantadin","abstract":"Bei Patienten mit einem Breakthrough oder Relapse nach einer Interferon-Monotherapie oder der Standard-Kombinationstherapie mit Interferon und Ribavirin erreichte eine Re-Therapie mit einer Dreifachkombination aus Interferon, Ribavirin und Amantadin eine hohe Rate an anhaltendem virologischen Response.","abstract_html":"Bei Patienten mit einem Breakthrough oder Relapse nach einer Interferon-Monotherapie oder der Standard-Kombinationstherapie mit Interferon und Ribavirin erreichte eine Re-Therapie mit einer Dreifachkombination aus Interferon, Ribavirin und Amantadin eine hohe Rate an anhaltendem virologischen Response.","abstract_has_math":false,"creators":["Lingenauber, Christoph"],"institution":"Universität Würzburg","degree_name":null,"degree_level":"thesis.doctoral","degree_discipline":null,"degree_department":null,"school":null,"contributors":["Klinker, Hartwig"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2004,"date_issued":"2004-07-16","date_published":"2004-07-16","updated_at":"2026-07-24T06:11:27Z","subjects":["Hepatitis C","Interferon","Ribavirin","Amantadin","amantadine"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/823","outbound_label":"Repository record","outbound_source":"source_url"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Klinker, Hartwig"]},{"key":"dc:creator","label":"Author","values":["Lingenauber, Christoph"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:publisher","label":"Institution","values":["Universität Würzburg"]},{"key":"dc:type","label":"Dc Type","values":["doctoralThesis"]},{"key":"thesis:degree_level","label":"Degree Level","values":["thesis.doctoral"]},{"key":"thesis:institution_name","label":"Thesis Institution Name","values":["Universität Würzburg"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Hepatitis C","Interferon","Ribavirin","Amantadin","amantadine"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Bei Patienten mit einem Breakthrough oder Relapse nach einer Interferon-Monotherapie oder der Standard-Kombinationstherapie mit Interferon und Ribavirin erreichte eine Re-Therapie mit einer Dreifachkombination aus Interferon, Ribavirin und Amantadin eine hohe Rate an anhaltendem virologischen Response.","In patients with a breakthrough or relapse after interferon monotherapy or standard combination therapy with interferon and ribavirin a re-therapy with a triple combination of interferon, ribavirin and amantadine results in a high rate of sustained virological response."]},{"key":"dc:format.medium","label":"Dc Format Medium","values":["application/pdf"]},{"key":"dc:title","label":"Title","values":["Viruslastorientierte Interferon-a-2a-Therapie der chronischen Hepatitis-C-Infektion in Kombination mit Ribavirin und Amantadin","Triple antiviral therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine"]}]}],"canonical_facts":{"dc:contributor":["Klinker, Hartwig"],"dc:creator":["Lingenauber, Christoph"],"dc:description.abstract":["Bei Patienten mit einem Breakthrough oder Relapse nach einer Interferon-Monotherapie oder der Standard-Kombinationstherapie mit Interferon und Ribavirin erreichte eine Re-Therapie mit einer Dreifachkombination aus Interferon, Ribavirin und Amantadin eine hohe Rate an anhaltendem virologischen Response.","In patients with a breakthrough or relapse after interferon monotherapy or standard combination therapy with interferon and ribavirin a re-therapy with a triple combination of interferon, ribavirin and amantadine results in a high rate of sustained virological response."],"dc:format.medium":["application/pdf"],"dc:publisher":["Universität Würzburg"],"dc:subject":["Hepatitis C","Interferon","Ribavirin","Amantadin","amantadine"],"dc:title":["Viruslastorientierte Interferon-a-2a-Therapie der chronischen Hepatitis-C-Infektion in Kombination mit Ribavirin und Amantadin","Triple antiviral therapy for chronic hepatitis C with interferon-alpha, ribavirin and amantadine"],"dc:type":["doctoralThesis"],"thesis:degree_level":["thesis.doctoral"],"thesis:institution_name":["Universität Würzburg"]},"updated_at":"2026-07-24T06:11:27Z"}